# Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

> **NCT00683904** · PHASE1 · COMPLETED · sponsor: **R-Pharm** · enrollment: 12 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL
- **DRUG:** Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL

## Key facts

- **NCT ID:** NCT00683904
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683904, "Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00683904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*